Understanding Your Prolactinoma Diagnosis
At a Glance
A prolactinoma is a highly treatable, non-cancerous tumor of the pituitary gland that overproduces the hormone prolactin. Most patients have an excellent long-term outlook and successfully manage the condition with medication, returning to normal hormone levels and a healthy quality of life.
Receiving a diagnosis of a prolactinoma can feel overwhelming, but it is important to know that you are not alone. This is a highly manageable condition, and most people with this diagnosis go on to live full, healthy lives with little to no impact on their long-term functional capacity [1][2].
What is a Prolactinoma?
A prolactinoma is a non-cancerous (benign) tumor of the pituitary gland, a pea-sized organ at the base of your brain that acts as your body’s “master gland” for hormones [3]. It is the most common type of functional pituitary tumor, accounting for approximately 45% to 50% of all pituitary adenomas [4][3].
These tumors are specifically called lactotroph adenomas because they develop from lactotroph cells—the specific cells in your pituitary gland responsible for making the hormone prolactin [4][5].
The Biological Mechanism
In a healthy body, the pituitary gland releases prolactin in carefully controlled amounts, primarily to support lactation (breast milk production) [5]. This release is normally kept in check by a chemical from the brain called dopamine, which acts like a “brake” to stop the cells from making too much hormone [6].
In the case of a prolactinoma:
- Overproduction: The tumor cells begin to produce prolactin uncontrollably, leading to high levels in the blood, a condition called hyperprolactinemia [5][1].
- Loss of Control: The tumor cells often lose their sensitivity to the inhibitory “braking” effect of dopamine, leading to further cell growth and hormone secretion [6].
- Hormonal Imbalance: High prolactin levels can interfere with other hormones, often leading to hypogonadotropic hypogonadism—a state where the body produces lower levels of sex hormones like estrogen or testosterone [7][8].
Frequency and Incidence
Prolactinomas are more common than many people realize. While exact figures can vary by region, population-based studies have shown an annual incidence rate of about 1.6 per 100,000 people [9]. In clinical registries, they represent roughly one-quarter of all diagnosed pituitary growths [10][11].
Long-Term Outlook
The general prognosis for someone diagnosed with a prolactinoma is excellent [1].
- Treatment Success: Most patients respond very well to first-line medications called dopamine agonists, which mimic the body’s natural dopamine to shrink the tumor and lower prolactin levels [12][13].
- Remission: In many cases, hormone levels return to normal, and symptoms disappear [14][8]. Remission can even be permanent for some patients after a period of successful treatment [2].
- Surgical Options: For those who do not respond well to medication, modern surgical techniques are highly effective and carry high success rates in specialized centers [15][2].
- Functional Capacity: Long-term studies show that with proper management, patients typically maintain their usual quality of life, work capacity, and fertility [14][2].
While this diagnosis requires ongoing care and monitoring, it is a condition that medical science understands well and can treat effectively.
Continue Reading
To help you navigate your diagnosis and treatment, we have prepared a comprehensive guide. Please read through the following sections to learn more:
Symptoms & Warning Signs: Recognizing Prolactinoma
Learn the warning signs of a prolactinoma. Understand how high prolactin causes irregular periods, low libido, headaches, vision changes, and bone loss.
Making Sure It's Truly a Prolactinoma (Diagnostic Pitfalls)
Learn about common prolactinoma diagnosis pitfalls. Understand the hook effect, stalk effect, macroprolactin, and how medications affect your prolactin levels.
Micro, Macro, and Giant Prolactinomas: What Size Means for You
Learn the differences between micro, macro, and giant prolactinomas. Understand how tumor size and genetics like MEN1 or AIP affect your treatment options.
Treatment Strategies: Medications vs. Surgery
Compare prolactinoma treatment options to make the right choice for your care. Learn about dopamine agonists like cabergoline versus transsphenoidal surgery.
Life After Diagnosis: Long-Term Monitoring and Medication Withdrawal
Learn about long-term prolactinoma care, including when you can stop taking cabergoline, monitoring heart valves and bone density, and managing scan anxiety.
Common questions in this guide
What is a prolactinoma?
What causes the hormone imbalance with a prolactinoma?
What is the long-term outlook for someone with a prolactinoma?
Can my hormone levels return to normal after starting treatment?
Will I need surgery to treat my prolactinoma?
Get notified when new evidence is published on Prolactinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Management outcomes of prolactinoma: a retrospective study from Southern Iraq.
Alobaidy HF, Alidrisi HA, Reman KA, et al.
Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.
PMID: 41178903 - 2
The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.
Zandbergen IM, Zamanipoor Najafabadi AH, Pelsma ICM, et al.
Trials 2021; (22(1)):653 doi:10.1186/s13063-021-05604-y.
PMID: 34563236 - 3
Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.
Dennison KL, Chack AC, Hickman MP, et al.
PloS one 2018; (13(9)):e0204727 doi:10.1371/journal.pone.0204727.
PMID: 30261014 - 4
Modern approach to bone comorbidity in prolactinoma.
Uygur MM, Menotti S, Santoro S, Giustina A
Pituitary 2024; (27(6)):802-812 doi:10.1007/s11102-024-01469-x.
PMID: 39541075 - 5
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
Hoffmann A, Adelmann S, Lohle K, et al.
European journal of pediatrics 2018; (177(1)):125-132 doi:10.1007/s00431-017-3042-5.
PMID: 29168011 - 6
Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V, Lamothe S, Beau I, et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018; (32(9)):4791-4797 doi:10.1096/fj.201701111RR.
PMID: 29596024 - 7
[Refractory pituitary prolactinoma:current treatment status and challenges].
Zhu HJ
Zhonghua yi xue za zhi 2025; (105(41)):3738-3742 doi:10.3760/cma.j.cn112137-20250824-02165.
PMID: 41218889 - 8
Diagnosis, misdiagnosis and management of hyperprolactinemia.
Healy ML, Smith TPP, McKenna TJ
Expert review of endocrinology & metabolism 2006; (1(1)):123-132 doi:10.1586/17446651.1.1.123.
PMID: 30743775 - 9
Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.
Oh JS, Kim HJ, Hann HJ, et al.
Pituitary 2021; (24(1)):38-47 doi:10.1007/s11102-020-01084-6.
PMID: 32949324 - 10
Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.
Mansour AA, Alhamza AHA, Almomin AMSA, et al.
F1000Research 2018; (7()):430 doi:10.12688/f1000research.13632.2.
PMID: 30026929 - 11
Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022.
Mohseni S, Mirdamadi N, Mossavarali S, et al.
Journal of diabetes and metabolic disorders 2024; (23(2)):2143-2149 doi:10.1007/s40200-024-01481-9.
PMID: 39610525 - 12
Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.
Schlegel A, Straseski JA
Laboratory medicine 2025; (56(6)):786-789 doi:10.1093/labmed/lmaf021.
PMID: 40493766 - 13
Management of cystic prolactinomas: a review.
Nakhleh A, Shehadeh N, Hochberg I, et al.
Pituitary 2018; (21(4)):425-430 doi:10.1007/s11102-018-0888-0.
PMID: 29654440 - 14
Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma.
Carlier L, Chanson P, Cazabat L, et al.
Journal of the Endocrine Society 2024; (8(9)):bvae135 doi:10.1210/jendso/bvae135.
PMID: 39109291 - 15
The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases.
van Trigt VR, Bakker LEH, Pelsma ICM, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(6)):e1833-e1844 doi:10.1210/clinem/dgae652.
PMID: 39292628
This page provides general educational information about prolactinoma diagnoses and biology. Always consult your endocrinologist or healthcare provider for medical advice and personalized treatment plans.